Citation Impact
Citing Papers
National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards
2006 Standout
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
2009 Standout
No health without mental health
2007 Standout
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses
2012 Standout
A new taxonomy for describing and defining adherence to medications
2012 Standout
Psychological disorder in asthma is associated with poor control and poor adherence to inhaled steroids
2001
Knowledge and intelligent computing system in medicine
2009 Standout
Cytokines, “Depression Due to A General Medical Condition,” and Antidepressant Drugs
1999
Kallikrein 6 Regulates Early CNS Demyelination in a Viral Model of Multiple Sclerosis
2012
Exercise and the Treatment of Clinical Depression in Adults
2002
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
2010 Standout
The Blood–Brain Barrier
2015 Standout
The cerebellum and cognition
2018 Standout
The Blood-Brain Barrier/Neurovascular Unit in Health and Disease
2005 Standout
Socioeconomic status and race are correlated with affective symptoms in multiple sclerosis
2020
Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms
2019 Standout
Medication adherence and persistence: A comprehensive review
2005
Structure and function of the blood–brain barrier
2009 Standout
MMPs in the central nervous system: Where the good guys go bad
2007
The Clinical Epidemiology of Multiple Sclerosis
2008
Emerging oral therapies for multiple sclerosis
2007
US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis
2005
Pediatric Multiple Sclerosis
2010
Cognitive impairment in multiple sclerosis
2008 Standout
Inflammation and cortisol response in coronary artery disease
2008
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis
2001
Pediatric Multiple Sclerosis
2011
The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure
2001 Standout
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
2018 Standout
Multiple sclerosis
2008 Standout
The role of the cerebellum in multiple sclerosis—150 years after Charcot
2018
Loneliness Matters: A Theoretical and Empirical Review of Consequences and Mechanisms
2010 Standout
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Quality of Life and Its Relationship to Brain Lesions and Atrophy on Magnetic Resonance Images in 60 Patients With Multiple Sclerosis
2000
Cytokines sing the blues: inflammation and the pathogenesis of depression
2005 Standout
Correlating Brain Atrophy With Cognitive Dysfunction, Mood Disturbances, and Personality Disorder in Multiple Sclerosis
2004
Patient Adherence and Medical Treatment Outcomes
2002 Standout
Patients With Depression Are Less Likely to Follow Recommendations to Reduce Cardiac Risk During Recovery From a Myocardial Infarction
2000
Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer
2006 Standout
Matrix metalloproteinases as modulators of inflammation and innate immunity
2004 Standout
The psychological impact of the COVID-19 epidemic on college students in China
2020 Standout
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2006 Standout
CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients
2017
The clinico-radiological paradox in multiple sclerosis revisited
2002
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
2011 Standout
The blood–brain-barrier in multiple sclerosis: Functional roles and therapeutic targeting
2007
How do immune cells overcome the blood–brain barrier in multiple sclerosis?
2011
Increased ability of peripheral blood lymphocytes to degrade laminin in multiple sclerosis
2004
Targeting leukocyte MMPs and transmigration
2002
Matrix metalloproteinases in neuroinflammation
2002
Multiple Sclerosis
2000 Standout
Traumatic spinal cord injury
2017 Standout
Kurtzke scales revisited: the application of psychometric methods to clinical intuition
2000
Noncompliance with antihypertensive medications
2002
Physical Activity and Public Health in Older Adults
2007 Standout
Depression in multiple sclerosis: a review
2005
An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis
2011 Standout
Gelatinase B/matrix metalloproteinase‐9 cleaves interferon‐β and is a target for immunotherapy
2003
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
An expert system for the evaluation of EDSS in multiple sclerosis
2002
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
Herpes-simplex virus encephalitis is characterized by an early MMP-9 increase and collagen type IV degradation
2006
Protein therapeutics: a summary and pharmacological classification
2007 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions
2007
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
2005 Standout
Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa
2001
Multiple sclerosis
2002 Standout
The psychometric properties of clinical rating scales used in multiple sclerosis
1999
The Epidemiology of Depression Across Cultures
2013 Standout
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
1998 Standout
The Natural History of Multiple Sclerosis
1995
Exercise and Physical Activity for Older Adults
2009 Standout
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
2000
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis
2006
Blood-brain barrier disruption in multiple sclerosis
2003
Amyloid β peptide cleavage by kallikrein 7 attenuates fibril growth and rescues neurons from Aβ-mediated toxicity in vitro
2013 StandoutNobel
Interferon-Beta Prevents Cytokine-Induced Neutrophil Infiltration and Attenuates Blood–Brain Barrier Disruption
2003
Depression and Coronary Heart Disease
2008 Standout
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis
2002
Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?
2019 Standout
Minocycline: far beyond an antibiotic
2013 Standout
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Depressogenic effects of medications: a review
2011
The clinical course of neuromyelitis optica (Devic’s syndrome)
1999 Standout
Physical Activity and Public Health in Older Adults
2007 Standout
Quality of life in multiple sclerosis
1999
The rising prevalence and changing age distribution of multiple sclerosis in Manitoba
2010 Standout
Psychological interventions for multiple sclerosis
2006
Medication Adherence
2009 Standout
Psychometric Properties of the Spanish Beck Depression Inventory-II in a Medical Sample.
2003
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study
2007
The Sources of Four Commonly Reported Cutoff Criteria
2006 Standout
Works of D Goodkin being referenced
IFN-β1a May Increase Serum Levels of TIMP-1 in Patients with Relapsing-Remitting Multiple Sclerosis
2001
Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS
2001
Interferon Beta-1a in Children with Multiple Sclerosis is Well Tolerated
2001
Course of Depression During the Initiation of Interferon Beta-1a Treatment for Multiple Sclerosis
1999
Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS)
1992
Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis
1997
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
1999
Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment
1996
IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS
2003